Ken Griffin Krystal Biotech, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 46,300 shares of KRYS stock, worth $7.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,300

Previous 27,400 68.98%

Holding current value

$7.34 Million

Previous $5.03 Million 67.34%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$174.7 - $213.66 $16,771 - $20,511	96 New	96 $17,000
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $1.82 Million - $3.02 Million	16,815 Added 205.09%	25,014 $4.45 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $365,664 - $488,656	3,809 Added 86.77%	8,199 $1.02 Million
Q3 2023 Nov 14, 2023	SELL	$108.51 - $130.22 $3.79 Million - $4.54 Million	-34,898 Reduced 88.83%	4,390 $509,000
Q2 2023 Aug 14, 2023	SELL	$78.48 - $130.32 $5.34 Million - $8.87 Million	-68,037 Reduced 63.39%	39,288 $4.61 Million
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $3.96 Million - $4.61 Million	54,649 Added 103.75%	107,325 $8.59 Million
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $2.77 Million - $3.51 Million	43,938 Added 502.84%	52,676 $4.17 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $566,659 - $720,011	8,738 New	8,738 $609,000
Q1 2022 May 16, 2022	SELL	$51.99 - $72.11 $1.56 Million - $2.16 Million	-30,013 Reduced 77.46%	8,732 $581,000
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $308,209 - $683,154	7,742 Added 24.97%	38,745 $2.71 Million
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $119,362 - $164,712	2,295 Added 7.99%	31,003 $1.62 Million
Q4 2020 Feb 16, 2021	BUY	$40.64 - $61.38 $182,229 - $275,227	4,484 Added 18.51%	28,708 $1.72 Million
Q3 2020 Nov 16, 2020	BUY	$37.76 - $48.49 $97,987 - $125,831	2,595 Added 12.0%	24,224 $1.04 Million
Q2 2020 Aug 14, 2020	SELL	$37.03 - $60.0 $19.3 Million - $31.2 Million	-520,073 Reduced 96.01%	21,629 $896,000
Q1 2020 May 15, 2020	BUY	$35.02 - $65.64 $170,022 - $318,682	4,855 Added 0.9%	541,702 $23.4 Million
Q4 2019 Feb 14, 2020	SELL	$33.17 - $65.23 $45,741 - $89,952	-1,379 Reduced 0.26%	536,847 $29.7 Million
Q3 2019 Nov 14, 2019	BUY	$34.72 - $51.3 $1.43 Million - $2.11 Million	41,056 Added 8.26%	538,226 $18.7 Million
Q2 2019 Aug 14, 2019	BUY	$27.2 - $41.2 $4.74 Million - $7.18 Million	174,296 Added 53.98%	497,170 $20 Million
Q1 2019 May 15, 2019	SELL	$19.86 - $32.9 $241,398 - $399,899	-12,155 Reduced 3.63%	322,874 $0
Q4 2018 Feb 14, 2019	BUY	$15.03 - $25.38 $5.04 Million - $8.5 Million	335,029 New	335,029 $6.96 Million

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.3M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.07B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account